Literature DB >> 21669429

Effects of the Kampo medication keishibukuryogan on blood pressure in perimenopausal and postmenopausal women.

Masakazu Terauchi1, Mihoko Akiyoshi, Yoko Owa, Kiyoko Kato, Satoshi Obayashi, Toshiro Kubota.   

Abstract

OBJECTIVE: To examine the effects of keishibukuryogan (TJ-25)-a medicine of the Kampo tradition (the Japanese adaptation of Chinese herbal medicine)-on middle-aged women with high blood pressure.
METHODS: The records of 77 peri- and postmenopausal women with high-normal blood pressure or hypertension were analyzed retrospectively. The women had participated in the Systematic Health and Nutrition Education Program at the Tokyo Medical and Dental University in Tokyo, Japan, and had received education only (controls; n = 47) or education and treatment with TJ-25 (n = 30).
RESULTS: The baseline characteristics of the 2 groups were comparable. After approximately 6 months, women in the TJ-25 group showed significant reductions in their systolic blood pressure (from 148.4mm Hg to 134.8mm Hg), diastolic blood pressure (from 89.7 mm Hg to 83.7 mm Hg), pulse rate (from 79.5 beats/min to 73.5 beats/min), and resting energy expenditure (from 1552 kcal/day to 1373 kcal/day). Several menopausal symptoms including perspiration, difficulty in initiating sleep, nonrestorative sleep, and headaches/dizziness were also improved. In addition, women in the TJ-25 group had increased health-related quality of life scores in the domains of physical health and life satisfaction.
CONCLUSION: TJ-25 alleviates menopausal symptoms and concurrently lowers the blood pressure of middle-aged women with high blood pressure.
Copyright © 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669429     DOI: 10.1016/j.ijgo.2011.03.006

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  7 in total

1.  Current state of yusho and prospects for therapeutic strategies.

Authors:  Chikage Mitoma; Hiroshi Uchi; Kiyomi Tsukimori; Takashi Todaka; Jumboku Kajiwara; Takayuki Shimose; Manabu Akahane; Tomoaki Imamura; Masutaka Furue
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-01       Impact factor: 4.223

2.  Subgrouping of Japanese middle-aged women attending a menopause clinic using physical and psychological symptom profiles: a cross-sectional study.

Authors:  Masakazu Terauchi; Asuka Hirose; Mihoko Akiyoshi; Yoko Owa; Kiyoko Kato; Toshiro Kubota
Journal:  BMC Womens Health       Date:  2014-11-25       Impact factor: 2.809

3.  Effect of Guizhifulingwan (Keishibukuryogan) on climacteric syndrome: study protocol for a randomized controlled pilot trial.

Authors:  Jung-Eun Kim; Junghyo Cho; Ojin Kwon; Ae-Ran Kim; Hyo-Ju Park; So-Young Jung; Joo-Hee Kim; Mikyung Kim; Hye-Yoon Lee; Jun-Hwan Lee
Journal:  Trials       Date:  2017-03-21       Impact factor: 2.279

4.  Dizziness in peri- and postmenopausal women is associated with anxiety: a cross-sectional study.

Authors:  Masakazu Terauchi; Tamami Odai; Asuka Hirose; Kiyoko Kato; Mihoko Akiyoshi; Mikako Masuda; Reiko Tsunoda; Hiroaki Fushiki; Naoyuki Miyasaka
Journal:  Biopsychosoc Med       Date:  2018-12-12

Review 5.  A Classic Herbal Formula Guizhi Fuling Wan for Menopausal Hot Flushes: From Experimental Findings to Clinical Applications.

Authors:  Mingdi Li; Andrew Hung; Hong Li; Angela Wei Hong Yang
Journal:  Biomedicines       Date:  2019-08-18

6.  Exploring the Mechanism of Gyejibokryeong-hwan against Atherosclerosis Using Network Pharmacology and Molecular Docking.

Authors:  A Yeong Lee; Joo-Youn Lee; Jin Mi Chun
Journal:  Plants (Basel)       Date:  2020-12-10

7.  Effects of the kampo formula tokishakuyakusan on headaches and concomitant depression in middle-aged women.

Authors:  Masakazu Terauchi; Shiro Hiramitsu; Mihoko Akiyoshi; Yoko Owa; Kiyoko Kato; Satoshi Obayashi; Eisuke Matsushima; Toshiro Kubota
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-04       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.